Having trouble accessing articles? Reset your cache.

IFM Therapeutics gets $55.5M to launch incubator and new subsidiaries

IFM Therapeutics is doubling down on its asset-centric subsidiary model, raising $55.5 million to launch an incubator and up to three new subsidiaries focused on developing small molecules targeted at the innate immune system for oncology and inflammatory disorders.

New investor Omega Funds led

Read the full 438 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE